• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    2/16/24 4:15:47 PM ET
    $SIEN
    Industrial Specialties
    Health Care
    Get the next $SIEN alert in real time by email
    false 0001551693 0001551693 2024-02-13 2024-02-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(D)
    OF THE SECURITIES ACT OF 1934

     

    Date of Report (Date of earliest event reported): February 13, 2024

     

     

     

    SIENTRA, INC.
    (Exact name of registrants as specified in its charters)

     

     

     

    Delaware   001-36709   20-5551000
    (State or other jurisdiction of
    incorporation or organization)
      (Commission File Number)   (I.R.S. Employer
    Identification Number)

     

    3333 Michelson Drive, Suite 650
    Irvine, California
      92612
    (Address of Principal Executive Offices)   (Zip Code)

     

    805-562-3500

    (Registrant’s telephone number, including area code)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   SIEN   The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    The information set forth below in Item 1.03 in this Current Report on Form 8-K (this “Current Report”) is hereby incorporated by reference into this Item 1.01.

     

    Item 1.03 Bankruptcy or Receivership.

     

    DIP Credit Agreement

     

    As previously disclosed, on February 12, 2024, Sientra, Inc. (the “Company”) and certain of its direct and indirect subsidiaries filed voluntary petitions to commence proceedings under chapter 11 (the “Chapter 11 Cases”) of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). The Chapter 11 Cases are being jointly administer under the caption In re Sientra, Inc., et al.

     

    On February 14 , 2024, the Company, as borrower and certain of the Company’s direct and indirect debtor-subsidiaries, as guarantors, entered into that certain multi-draw senior secured super-priority priming term loan debtor-in-possession credit agreement and guaranty (the “DIP Credit Agreement”), with the Lenders from time to time party thereto, and Deerfield Partners L.P., as agent for the DIP Lenders, on the terms and conditions set forth therein. Capitalized terms used but not otherwise defined in this Current Report shall have the meanings given to them in the DIP Credit Agreement. The description of the DIP Credit Agreement included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on February 13, 2024, in Item 1.03 under the caption “DIP Credit Agreement” is hereby incorporated by reference. The foregoing description of the DIP Credit Agreement does not purport to be complete and is qualified in its entirety by reference to the DIP Credit Agreement, which is attached to this Current Report as Exhibit 10.1 and is incorporated herein by reference.

     

    On February 14, 2024, the Bankruptcy Court entered an order approving the DIP Credit Agreement on an interim basis.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On February 13, 2024, the Company received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, it had determined that the Company’s common stock will be delisted from The Nasdaq Stock Market (“Nasdaq”). The Company does not intend to appeal this determination.

     

    Trading of the Company’s common stock will be suspended at the opening of business on February 22, 2024, and Nasdaq will file a Form 25-NSE with the SEC, which will remove the Company’s common stock from listing and registration on Nasdaq.

     

    As a result of the suspension and expected delisting, the Company expects its common stock to commence trading in the OTC Pink Marketplace under the symbol “SIENQ”. The OTC Pink Marketplace is a significantly more limited market than Nasdaq, and quotation on the OTC Pink Marketplace likely results in a less liquid market for existing and potential holders of the common stock to trade the common stock and could further depress the trading price of the common stock. The Company can provide no assurance that its common stock will continue to trade on this market, whether broker-dealers will continue to provide public quotes of the common stock on this market, or whether the trading volume of the common stock will be sufficient to provide for an efficient trading market. The transition to over-the-counter markets will not affect the Company’s business operations or its reporting requirements under the rules of the SEC.

     

    1

     

     

    Item 8.01 Other Events.

     

    Cautionary Note Regarding the Company’s Securities

     

    The Company cautions that trading in its securities during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Cases. In particular, the Company expects that its equity holders could experience a significant or complete loss on their investment, depending on the outcome of the Chapter 11 Cases.

     

    Cautionary Statement Regarding Forward-Looking Statements

     

    This Current Report contains “forward-looking statements” related to future events. Forward-looking statements contain words such as “expect,” “anticipate,” “could,” “should,” “intend,” “plan,” “believe,” “seek,” “see,” “may,” “will,” “would” or “target.” Forward-looking statements are based on management’s current expectations, beliefs, assumptions and estimates. These statements are subject to significant risks, uncertainties and assumptions that are difficult to predict and could cause actual results to differ materially and adversely from those expressed or implied in the forward-looking statements, including risks and uncertainties regarding: the Company’s ability to obtain court approval from the Bankruptcy Court with respect to motions or other requests made to the Bankruptcy Court throughout the course of the Chapter 11 Cases, including with respect to any final orders relating to the DIP Credit Agreement; the Company’s ability to access the full amount available under the DIP Credit Agreement which requires the satisfaction of certain conditions that may not be satisfied for various reasons, including for reasons outside of the Company’s control; the ability of the Company to negotiate, develop, confirm and consummate a sale of all or substantially all of the Company Parties’ assets; the effects of the Chapter 11 Cases, including increased legal and other professional costs necessary to execute the sale of all or substantially all of the Company Parties’ assets, on the Company’s liquidity (including the availability of operating capital during the pendency of the Chapter 11 Cases), results of operations or business prospects; the effects of the Chapter 11 Cases on the interests of various constituents; the length of time that the Company will operate under Chapter 11 protection; risks associated with third-party motions in the Chapter 11 Cases; Bankruptcy Court rulings in the Chapter 11 Cases and the outcome of the Chapter 11 Cases in general; the Company’s anticipated delisting of its common stock from Nasdaq and trading of the Company’s common stock on the OTC Pink Marketplace; general economic conditions, including inflation, recession, unemployment levels, consumer confidence and spending patterns, credit availability and debt levels; the Company’s ability to attract, motivate and retain key executives and other associates; the impact of cost reduction initiatives; the Company’s ability to generate or maintain liquidity and legal and regulatory proceedings. Forward-looking statements are also subject to the risk factors and cautionary language described from time to time in the reports the Company files with the SEC, including those in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2022 and any updates thereto in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These risks and uncertainties may cause actual future results to be materially different than those expressed in such forward-looking statements. Sientra has no obligation to update or revise these forward-looking statements and does not undertake to do so.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Numbers   Description
    10.1*   Multi-Draw Senior Secured Super-Priority Priming Debtor-In-Possession Credit Agreement, dated as of February 14, 2024, by and among Sientra, Inc., the other loan parties thereto and Deerfield Partners L.P.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    *In accordance with Item 601(a)(5) of Regulation S-K, certain schedules or similar attachments to this exhibit have been omitted from this filing.

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: February 16, 2024 SIENTRA, INC.
       
      By: /s/ Ronald Menezes
        Ronald Menezes
        President and Chief Executive Officer

     

     

    3

     

     

    Get the next $SIEN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SIEN

    DatePrice TargetRatingAnalyst
    4/14/2022$8.00Buy
    Lake Street
    More analyst ratings

    $SIEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Menezes Ronald covered exercise/tax liability with 3,625 shares, decreasing direct ownership by 18% to 16,775 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:38 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Van Hove Caroline F. covered exercise/tax liability with 741 shares, decreasing direct ownership by 8% to 8,239 units (SEC Form 4)

      4 - Sientra, Inc. (0001551693) (Issuer)

      11/14/23 3:50:11 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form 4: Bennett Oliver Christian was granted 2,739 shares, increasing direct ownership by 13% to 23,100 units

      4 - Sientra, Inc. (0001551693) (Issuer)

      9/11/23 9:05:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction

      Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra's breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra's BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. ("Sientra" or the "Company") announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC ("Tiger") has been declared the successful bidder for certain of the assets of Sientra used in its breast reconstruction and augmentation business. As consideration for the acquisition, Tiger will pay a cash consid

      4/2/24 6:30:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

      IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on February 12, 2024. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. The Company seeks to execute an expedited sale process. Sientra will utilize existing cash reserves and $22.5 million in new money d

      2/13/24 8:30:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Financials

    Live finance-specific insights

    See more
    • Sientra Reports Third Quarter Financial and Operational Results

      IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, approximately flat from $65.5 million for the same period in 2022.Free cash flow usage of $3.6 million, a slight improvement from $3.7 million in the same period in 2022

      11/9/23 4:05:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook

      IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million in the prior year period. Third quarter results were adversely affected by overall softness in the market as well as more pronounced seasonal headwinds that led to a reduced number of augmentation and reconstru

      10/30/23 5:00:51 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Reports Record Second Quarter Financial and Operational Results

      Revenue growth of 7.5% driven by continued market share gains in reconstruction and augmentation Best operational results in company history with 95% and 63% year-over-year improvement inoperating cash flow and adjusted EBITDA respectively Continued success in advancing products through the FDA regulatory process with clearance of Allox2 Pro™, the first and only FDA-cleared MRI-compatible tissue expander IRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the second quarter tha

      8/10/23 4:03:00 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    SEC Filings

    See more
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/16/24 4:15:47 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      2/13/24 9:00:40 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sientra, Inc. (0001551693) (Filer)

      1/29/24 6:07:11 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Sientra with a new price target

      Lake Street initiated coverage of Sientra with a rating of Buy and set a new price target of $8.00

      4/14/22 9:15:44 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Canaccord Genuity reiterated coverage on Sientra with a new price target

      Canaccord Genuity reiterated coverage of Sientra with a rating of Buy and set a new price target of $10.00 from $9.00 previously

      5/12/21 11:21:33 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SVB Leerink reiterated coverage on Sientra with a new price target

      SVB Leerink reiterated coverage of Sientra with a rating of Outperform and set a new price target of $11.00 from $10.00 previously

      5/12/21 7:20:27 AM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sientra Inc. (Amendment)

      SC 13G/A - Sientra, Inc. (0001551693) (Subject)

      2/20/24 1:38:37 PM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/6/24 10:00:53 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Sientra Inc.

      SC 13G - Sientra, Inc. (0001551693) (Subject)

      2/15/23 3:19:14 PM ET
      $SIEN
      Industrial Specialties
      Health Care

    $SIEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Sientra Announces Appointment of Alexander W. Casdin to Board of Directors

      IRVINE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced the appointment of Alexander W. Casdin to the Company's Board of Directors, effective June 15, 2023. "On the heels of no less than 3 new product approvals in the United States in the past 12 months, and with continued strong topline performance and a near-term path to profitability, we are delighted to welcome Alex to the Sientra Board of Directors," said Caro Van Hove, Executive Chair of Sientra. "With Kevin O'Boyle retiring from the Board after nearly a decade of exceptional

      6/20/23 8:35:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

      SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021. "We are extremely pleased to welcome Irina and Nori to the Sientra Board," said Caroline Van Hove, Executive Chairwoman of Sientra. "Irina and Nori's deep respective experiences and competencies in building disruptive R&D engines and best-in-class organizations in Medical Aesthetics will significantly contribute to Sientra's high-growth strategy and our singular focus to be the number one

      7/19/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care
    • Sientra Announces Appointment of Chief Financial Officer

      SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ:SIEN) ("Sientra" or the "Company"), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations. "We are extremely pleased to welcome a strong leader like Andy to the Sientra team. His experience with growth-oriented public companies will be invaluable as we work towards expanding our market share and advancing the art of plastic surgery," said Ron Menezes, President and Chief Executive Of

      7/12/21 8:00:00 AM ET
      $SIEN
      Industrial Specialties
      Health Care